Italy: Added Benefit Will Be Key To Reimbursement
Executive Summary
A draft decree in Italy aims to put added therapeutic value at the centre of reimbursement decisions.
You may also be interested in...
Italy To Consult On Pricing Transparency Requirements
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
New Italian Pricing Decree To Drive R&D Transparency
Following on from moves to push price transparency on to the global agenda, Italy is poised to pass a decree that would oblige companies to disclose public R&D funding.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.